This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Panchal, V. R. Articles by March, K. L. Search for Related Content PubMed PubMed Citation Articles by Panchal, V. R. Articles by March, K. L.

Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease

Vipul R. Panchal, MD^*, Jalees Rehman, MD^*, Anne T. Nguyen, MS^*, John W. Brown, MD, Mark W. Turrentine, MD, Yousuf Mahomed, MD and Keith L. March, MD, PhD^*,*

^* Department of Medicine, Krannert Institute of Cardiology, Indianapolis, Indiana, USA
Department of Surgery, Thoracic Surgery Section, Indiana University School of Medicine, Indianapolis, Indiana, USA

View larger version (35K): [in a new window]   Figure 1 Vascular endothelial growth factor (VEGF) and endostatin levels in patients grouped with respect to gender, presence or absence of diabetes mellitus (DM), acute coronary syndrome (ACS) (present or absent), and ejection fraction (EF) (<35% or >35%). There are no statistically significant differences shown in either VEGF or endostatin with respect to any of these factors.

View larger version (22K): [in a new window]   Figure 2 Vascular endothelial growth factor (VEGF) and endostatin levels in patients without angiographically visible collaterals (Rentrop grade 0) versus those with robust angiographically visible colaterals (Rentrop grade 3). Although VEGF is not different between these populations, endostatin is reduced by 40%, with strong significance, in the patient group that has manifested the growth of prominent collaterals.